Evidence map›Paper›PMID 32352644›Full record

Trial reportObesity (Silver Spring, Md.)2020

Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.

Gianluca Iacobellis, Silvia Gra-Menendez

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Obesity (Silver Spring, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05565976. Cited by 79 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 5 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05565976 phase2 / phase3unknown status

Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

Ran2020Enrolled270Registered outcomes3Posted comparisons0ConditionsDementia, Vascular, Metabolic Syndrome, Mild Cognitive Impairment, Stroke, IschemicArmsAntidiabetic, Dapagliflozin 10mg Tab, Platelet Antiaggregant, Statins (Cardiovascular Agents)
PMID 29573529PMID 34813630PMID 33894597PMID 33282811PMID 33030307PMID 32854852PMID 32559474PMID 32317958PMID 32178931PMID 32144994PMID 32115470PMID 31535829other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 5 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Heart failure with preserved ejection fraction: current insights and emerging therapeutic directions.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Review
  14. Article
  15. Article
  16. Review
  17. Epicardial adipose tissue in coronary microvascular disease.American heart journal plus : cardiology research and practice · 2026
    Review
  18. Review
  19. Article
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Gianluca IacobellisDivision of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA.ORCID 0000-0001-7888-9530
Silvia Gra-MenendezDivision of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA.
University of Miami · US

Funding

Astra Zeneca
6 · The paper itself

Abstract

objectiveEpicardial adipose tissue (EAT) thickness is a marker of visceral fat and an emerging therapeutic target. Dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, improves glucose control and induces moderate weight loss in patients with type 2 diabetes mellitus. Dapagliflozin has recently been shown to reduce cardiovascular risk. Nevertheless, whether dapagliflozin could reduce EAT thickness is unknown.

methodsThis hypothesis was tested in a 24-week, randomized, double-blind, placebo-controlled clinical trial in 100 patients with type 2 diabetes mellitus with BMI ≥ 27 kg/m

resultsIn the dapagliflozin group, EAT decreased by 20% from baseline to 24 weeks, by 15% after 12 weeks, and by 7% between 12 and 24 weeks, respectively (P < 0.01 for all), whereas in the metformin group, there was a significant but smaller EAT reduction. There was no statistically significant correlation between EAT and body weight changes.

conclusionsDapagliflozin causes a rapid and significant EAT reduction that could be independent of weight loss.

Indexed as

Adipose TissueBenzhydryl CompoundsDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucosidesHumansHypoglycemic AgentsMaleMiddle AgedObesitySodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsdapagliflozinGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID32352644
OpenAlexW3021820898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.